Alibašić Esad, Skopljak Amira, Čengić Aida, Krstović Gorana, Trifunović Nataša, Čatić Tarik, Kapo Belma, Mehić Meliha, Hadžimuratović Amila
Department of Family Medicine, Primary Health Care Center Kalesija, Kalesija, Bosnia and Herzegovina.
Health Care Centre of Canton Sarajevo, Sarajevo, Bosnia and Herzegovina.
Med Glas (Zenica). 2017 Aug 1;14(2):182-188. doi: 10.17392/906-17.
Aim To investigate the effects of carbocisteine treatment in the reduction of frequency of productive cough episodes, preventing disease progression and improving the quality of life as well as the tolerability of the administered treatment and patient compliance during the study. Methods This observational, non-interventional, multicenter, cohort study included 501 patients with chronic obstructive pulmonary disease (COPD) who were administrated carbocisteine capsules 375 mg and followed up during the next 15 days. The patients were observed at 3 points, baseline and two additional assessments. General clinical condition of patients, along with the spirometry testing at all three points were examined. Thr quality of life was assessed on the 1st and 3rd observation with Leicester Cough Questionnaire. Tolerability and patient compliance were measured throughout the study. Results There was a significant change of forced expiratory volume in 1 second (FEV1) status between the second and third observation (p=0.002). Examination of general symptoms showed a statistically significant reduction in cough by 74.9%, in sputum production by 48.5%, in dyspnea by 29% and in fatigue by 50%. After the administration of carbocisteine the median value of overall quality of life was 3.79 (3.63 - 3.89). Conclusion 375mg carbocisteine capsules were found to be effective and well-tolerated in the treatment of COPD, with a small percentage of reported mild adverse reactions and with a significant improvement of quality of life.
目的 研究羧甲司坦治疗对减少咳痰性咳嗽发作频率、预防疾病进展、改善生活质量以及治疗耐受性和患者依从性的影响。方法 这项观察性、非干预性、多中心队列研究纳入了501例慢性阻塞性肺疾病（COPD）患者，给予其375mg羧甲司坦胶囊，并在接下来的15天内进行随访。在3个时间点对患者进行观察，即基线期以及另外两次评估。检查患者的一般临床状况，并在所有3个时间点进行肺功能测试。在第1次和第3次观察时使用莱斯特咳嗽问卷评估生活质量。在整个研究过程中测量耐受性和患者依从性。结果 第2次和第3次观察之间，1秒用力呼气容积（FEV1）状态有显著变化（p=0.002）。一般症状检查显示，咳嗽减少74.9%、痰液生成减少48.5%、呼吸困难减少29%、疲劳减少50%，差异均有统计学意义。服用羧甲司坦后，总体生活质量的中位数为3.79（3.63 - 3.89）。结论 发现375mg羧甲司坦胶囊治疗COPD有效且耐受性良好，报告的轻度不良反应比例较小，生活质量有显著改善。
